# Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

> **NCT05051592** · — · UNKNOWN · sponsor: **National University Hospital, Singapore** · enrollment: 40 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05051592
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-26
- **Primary completion:** 2022-09
- **Final completion:** 2022-09
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05051592

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05051592, "Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05051592. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*